TNF and cancer: In the ORAL Surveillance study (NCT02092467), the incidence of cancer and major adverse cardiovascular events (MACE) were compared among groups of patients receiving tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and a tumor necrosis factor inhibitor.